Synergism and antagonism in chemotherapy:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | Undetermined |
| Veröffentlicht: |
San Diego u.a.
Acad. Press
1991
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XVI, 752 S. Ill., zahlr. graph. Darst. |
| ISBN: | 0121740900 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV004708057 | ||
| 003 | DE-604 | ||
| 005 | 19920403 | ||
| 007 | t | ||
| 008 | 920210s1991 ad|| |||| 00||| undod | ||
| 020 | |a 0121740900 |9 0-12-174090-0 | ||
| 035 | |a (OCoLC)231275764 | ||
| 035 | |a (DE-599)BVBBV004708057 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | |a und | ||
| 049 | |a DE-12 |a DE-19 |a DE-355 | ||
| 084 | |a XI 3200 |0 (DE-625)152994: |2 rvk | ||
| 245 | 1 | 0 | |a Synergism and antagonism in chemotherapy |c ed. by Ting-chao Chou ... |
| 264 | 1 | |a San Diego u.a. |b Acad. Press |c 1991 | |
| 300 | |a XVI, 752 S. |b Ill., zahlr. graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben | ||
| 650 | 0 | 7 | |a Antagonist |0 (DE-588)4198647-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Agonist |0 (DE-588)4380725-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakologischer Antagonist |0 (DE-588)4198682-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Synergie |0 (DE-588)4200199-7 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
| 689 | 0 | 1 | |a Synergie |0 (DE-588)4200199-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
| 689 | 1 | 1 | |a Pharmakologischer Antagonist |0 (DE-588)4198682-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 2 | 1 | |a Pharmakologischer Antagonist |0 (DE-588)4198682-9 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 3 | 1 | |a Synergie |0 (DE-588)4200199-7 |D s |
| 689 | 3 | |5 DE-604 | |
| 689 | 4 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 4 | 1 | |a Agonist |0 (DE-588)4380725-2 |D s |
| 689 | 4 | |8 1\p |5 DE-604 | |
| 689 | 5 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 5 | 1 | |a Antagonist |0 (DE-588)4198647-7 |D s |
| 689 | 5 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Zhou, Dingzhao |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002893247&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-002893247 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804118825987211264 |
|---|---|
| adam_text | SYNERGISM AND ANTAGONISM IN CHEMOTHERAPY EDITED BY TING-CHAO CHOU
MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, NEW YORK DARRYL C.
RIDEOUT THE RESEARCH INSTITUTE OFSCRIPPS CLINIC LA JOLLA, CALIFORNIA
ACADEMIC PRESS, INC. HARCOURT BRACE JOVANOVICH, PUBLISHERS SAN DIEGO NEW
YORK BOSTON LONDON SYDNEY TOKYO TORONTO CONTENTS CONTRIBUTORS XIII
PREFACE XV PARTI REVIEWS AND METHODS OF QUANTITATION CHAPTER 1
SYNERGISM, ANTAGONISM, AND POTENTIATION IN CHEMOTHERAPY: AN OVERVIEW 3
DARRYL C. RIDEOUT AND TING-CHAO CHOU I. DRUG COMBINATIONS IN
CHEMOTHERAPY 6 II. MECHANISMS OF INTERACTION 25 III. CONDITION-RELATED
ASPECTS OF SYNERGISM, ; ANTAGONISM, AND POTENTIATION 51 REFERENCES 53
CHAPTER 2 THE MEDIAN-EFFECT PRINCIPLE AND THE COMBINATION INDEX FOR
QUANTITATION OFSYNERGISM AND ANTAGONISM 61 TING-CHAO CHOU I.
INTRODUCTION 62 II. DOSE-EFFECT ANALYSIS WITH PHYSICOCHEMICAL APPROACH
AS OPPOSED TO EMPIRICAL APPROACH 62 III. THE MEDIAN-EFFECT PRINCIPLE OF
THE MASS-ACTION LAW 65 IV. DOSE-EFFECT ANALYSIS OF COMBINED DRUG EFFECTS
69 V. SUMMARY 88 REFERENCES 101 CHAPTER 3 CLINICAL STUDIES OF
COMBINATION CHEMOTHERAPY FOR CANCER 103 EMIL FREI III REFERENCES 107
CHAPTER 4 COMBINED CHEMOTHERAPEUTIC MODALITIES FOR VIRAL INFECTIONS:
RATIONALE AND CLINICAL POTENTIAL 109 RAYMOND F. SCFFLNAZI I.
INTRODUCTION 110 II. CURRENT STATUS OF RESEARCH ILL IIL RATIONALE FOR
COMBINED THERAPY WITH ANTIVIRAL DRUGS 136 IV. CRITERIA FOR USEFULNESS OF
COMBINATION CHEMOTHERAPY WITH ANTIVIRAL AGENTS 139 V. METHODS OF
ANALYSIS OF DRUG INTERACTIONS 139 VI. MECHANISMS OF INTERACTION 140 VII.
PHARMACOLOGICAL PRINCIPLES 143 VIII. TREATMENT OF HIV, OPPORTUNISTIC
INFECTIONS, AND MALIGNANCIES 146 IX. DRUG COMBINATIONS AS A CHALLENGE
FOR DRUG-RESISTANT VIRUSES 148 X. COMBINATION CHEMOTHERAPY AND COMBINED
MODALITIES FOR VIRUSES: RESULTS AND PROPOSED MECHANISMS OF INTERACTION
150 XI. PROSPECTS 158 REFERENCES 160 CHAPTER 5 ANTIMALARIAL SYNERGISM
AND ANTAGONISM 183 J. L. VENNERSTROM, W. Y. ELLIS, W. K. MILHOUS, AND J.
W. EATON I. INTRODUCTION 183 II. ANTIFOLS 184 III. COMBINATIONS OF
ANTIFOLS WITH OTHER ANTIMALARIAL DRUGS 190 IV. QUINOLINES 192 V.
QUINOLINE/ANTIBIOTIC COMBINATIONS 195 VI. ARTEMISININ COMBINATIONS 196
VII. OXIDANTS/OXIDANT DRUGS AND OTHER FACTORS IN COMBINATION 197 VIII.
NUTRITIONAL SYNERGISM AND ANTAGONISM 201 IX. CHELATORS AS POTENTIAL
ANTIMALARIALS 201 VI X. MISCELLANEOUS COMBINATIONS 207 XI. RESISTANCE
MODULATORS AS ADJUNCT ANTIMALARIAL CHEMOTHERAPY 209 REFERENCES 211
CHAPTER 6 QUANTITATION OFSYNERGISM AND ANTAGONISM OF TWO OR MORE DRUGS
BY COMPUTERIZED ANALYSIS 223 JOSEPH H. CHOU I. THEORY AND EQUATIONS 224
II. COMPUTERIZED SIMULATION AND AUTOMATION 225 III. ILLUSTRATION OF
ANALYSIS WITH EXAMPLES 230 IV. OTHER APPLICATIONS AND FUTURE
DEVELOPMENTS 237 REFERENCES 241 PART II MECHANISMS OF INTERACTION
CHAPTER 7 INHIBITION OF METABOLIC DRUG INACTIVATION: MODULATION OF DRUG
ACTIVITY AND TOXICITY BY PERTURBATION OF GLUTATHIONE METABOLISM 245 OWEN
W. GRIFFITH AND HENRY S. FRIEDMAN I. INTRODUCTION 246 II. GLUTATHIONE
METABOLISM AND TURNOVER 247 III. GLUTATHIONE AS A CELLULAR PROTECTANT
255 IV. PHARMACOLOGICAL CONTROL OF GLUTATHIONE LEVELS AND METABOLISM 259
V. THERAPEUTIC APPLICATIONS OF PHARMACOLOGIC MANIPULATIONS OF
GLUTATHIONE LEVELS OR METABOLISM 271 VI. GLUTATHIONE MODULATION:
PERSPECTIVE ON FURTHER APPLICATIONS : 27 7 REFERENCES 279 CHAPTER 8
SYNERGY AND ANTAGONISM IN POLYMERASE-TARGETED ANTIVIRAL THERAPY: EFFECTS
OF DEOXYNUCLEOSIDE TRIPHOSPHATE POOL MODULATION ON PRODRUG ACTIVATION
285 THOMAS SPECTOR AND JAMES A. FYFE I. SYNERGISTIC ANTIHERPETIC
CHEMOTHERAPY BY ACYCLOVIR (ACV) AND AN INHIBITOR OF HERPES VIRUS
RIBONUCLEOTIDE REDUCTASE 286 II. ANTAGONISM OF
3 -AZIDO-3 -DEOXYTHYMIDINE (AZT) ANTIVIRAL ACTION BY RIBAVIRIN (RBV) 297
III. SUMMARY 305 REFERENCES 306 CHAPTER 9 REVERSAL OF MULTIDRUG
RESISTANCE IN TUMOR CELLS 311 C.-P. HUANG YANG, L. M. GREENBERGER, AND
S. B. HORWITZ I. INTRODUCTION 311 II. REVIEW OF THE MULTIDRUG RESISTANCE
PHENOTYPE 312 III. REVERSAL OF MULTIDRUG RESISTANCE PHENOTYPE 315 IV.
MECHANISMS INVOLVED IN REVERSION OF MULTIDRUG RESISTANCE 328 V. CLINICAL
IMPLICATIONS 329 VI. SUMMARY 331 REFERENCES 332 CHAPTER 10 BIOCHEMICAL
MECHANISMS OF THE SYNERGISTIC INTERACTION OF ANTIFOLATES .? ACTING ON
DIFFERENT ENZYMES OFFOLATE METABOLIC PATHWAYS 339 JOHN GALIVAN I.
INTRODUCTION 339 II. RATIONALE 343 III. THE EFFECTS OF COMBINED
ANTIFOLATES 348 IV. DISCUSSION, CONCLUSIONS, AND PROSPECTS 355
REFERENCES 357 CHAPTER 11 SYNERGISTIC AND ANTAGONISTIC DRUG INTERACTIONS
RESULTING FROM MULTIPLE INHIBITION OF METABOLIC PATHWAYS 363 ROBERT C.
JACKSON I. INTRODUCTION: SIMULTANEOUS INHIBITION EFFECTS AS A
DETERMINANT OF THE EFFICACY OF DRUG COMBINATIONS 364 II. SEQUENTIAL
INHIBITION: A HISTORICAL PERSPECTIVE 368 III. THE CELL AS AN OPEN SYSTEM
IN A STEADY STATE 374 IV. THE MAIN PATTERNS OF MULTIPLE INHIBITOR USE
378 V. MULTIPLE INHIBITION IN HIGHLY REGULATED SYSTEMS 388 VI.
APPROACHES TO A GENERAL THEORY OF MULTIPLE INHIBITION 394 VII.
CONCLUSIONS: COMBINING INHIBITORS TO OPTIMIZE SELECTIVITY 398 APPENDIX:
A BASIC PROGRAM TO ILLLUSTRATE THE CONCLUSIONS 403 REFERENCES 407
CHAPTER 12 ENHANCED EFFECTS OF DRUGS THAT BIND SIMULTANEOUSLY TO THE
SAME MACROMOLECULAR TARGET 409 LUCJAN STREKOWSKI AND W. DAVID WILSON I.
INTRODUCTION 409 II. INTERACTIONS WITH NUCLEIC ACIDS 410 III.
INTERACTIONS WITH PROTEIN TARGETS 436 REFERENCES 438 CHAPTER 13
BIOCHEMICAL MODULATION OF 5-FLUOROURACIL BY METABOLITES AND
ANTIMETABOLITES 449 ENRICO MINI AND JOSEPH R. BERTINO I. INTRODUCTION
449 II. MECHANISM OF ACTION OF FURA 451 III. SEQUENTIAL
METHOTREXATE-FURA A 452 IV. LEUCOVORIN-FURA 464 V. SEQUENTIAL
MTX-LV-FURA 475 VI. 6-METHYLMERCAPTOPURINE RIBONUCLEOSIDE-FURA 477 VII.
PHOSPHONACETYL-L-ASPARTIC ACID AND/OR THYMIDINE-FURA 477 VIII.
HYDROXYUREA-FURA 482 IX. DIPYRIDAMOL-FURA 482 X. PURINES-FURA 483 XL
ALLOPURINOL-FURA 484 XII. URIDINE-FURA 485 XIII. CONCLUSIONS 487
REFERENCES 488 CHAPTER 14 SYNERGISM AND ANTAGONISM THROUGH DIRECT BOND
FORMATION BETWEEN TWO AGENTS IN SITU 507 DARRYL C. RIDEOUT AND THEODORA
CALOGEROPOULOU I. INTRODUCTION 508 II. NONBIOCHEMICAL CONDENSATION
REACTIONS OCCURING IN VIVO OR UNDER NEAR-PHYSIOLOGICAL CONDITIONS 508
III. ENHANCED CYTOTOXIC AND ANTIMICROBIAL BIOACTIVITY OF POLYFUNCTIONAL
VERSUS MONOFUNCTIONAL MOLECULES 512 IV. SYNERGISM INVOLVING COVALENT
SELF-ASSEMBLY OF CYTOTOXIC AND ANTIMICROBIAL AGENTS FROM LESS BIOACTIVE
PRECURSORS 520 V. ANTAGONISM INVOLVING COVALENT SELF-ASSEMBLY 528
REFERENCES 534 CHAPTER 15 CHEMOTHERAPEUTIC POTENTIATION THROUGH
INTERACTION AT THE LEVEL OFDNA 541 BEVERLY A. TEICHER, TERENCE S.
HERMAN, AND J. PAUL EDER I. ISOBOLOGRAM METHODOLOGY 542 II. COMBINATIONS
OF ALKYLATING AGENTS AND REPAIR INHIBITORS 545 III. COMBINED ALKYLATING
AGENT STUDIES 562 IV. NITROIMIDAZOLE AND PERFLUOROCHEMICAL EMULSION/O 2
CHEMOTHERAPY COMBINATIONS 570 REFERENCES 576 CHAPTER 16 . DRUG
SYNERGISM, ANTAGONISM, AND COLLATERAL SENSITIVITY INVOLVING GENETIC
CHANGES 58 5 VASSILIOS I. AVRAMIS, SHENG-HE HUANG, AND JOHN S.
HOLCENBERG I. INTRODUCTION 585 II. OVER-EXPRESSION OF GENES 586 III.
UNDER-EXPRESSION OF GENES 589 REFERENCES 616 PART III
CONDITION-SELECTIVE SYNERGISM AND ANTAGONISM CHAPTER 17
SCHEDULE-DEPENDENT EFFECTS IN ANTINEOPLASTIC SYNERGISM AND ANTAGONISM
623 BARBARA K. CHANG I. INTRODUCTION 623 II. SCHEDULE-DEPENDENT
INTERACTIONS BASED UPON CELL CYCLE CONSIDERATIONS 626 III.
SCHEDULE-DEPENDENT INTERACTIONS BASED PRIMARILY UPON BIOCHEMICAL
CONSIDERATIONS: COMBINATIONS (LARGELY OF ANTIMETABOLITES) AFFECTING THE
ENZYMES INVOLVED IN DNA SYNTHESIS 638 IV. INTERACTIONS BASED UPON
ALTERED DRUG TRANSPORT 643 V. MISCELLANEOUS 646 VI. SUMMARY 647
REFERENCES 648 CHAPTER 18 EFFECTS OF DRUG DISTRIBUTION AND CELLULAR
MICROENVIRONMENT ON THE INTERACTION OF CANCER CHEMOTHERAPEUTIC AGENTS
659 RALPH E. DURAND I. OVERVIEW 659 II. INTRODUCTION 660 III.
QUANTITATIVE TECHNIQUES FOR HETEROGENEOUS SYSTEMS 664 IV. INTERACTION OF
CHEMOTHERAPEUTIC AGENTS 672 V. ADDITIONAL CONSIDERATIONS 681 REFERENCES
684 CHAPTER 19 SYNERGISTIC INTERACTIONS AT THE SOLID TUMOR LEVEL THROUGH
TARGETING OF THERAPIES AGAINST TWO OR MORE DIFFERENT TUMOR CELL
SUBPOPULATIONS 68 9 DIETMAR W. SIEMANN AND PETER C. KENG I. INTRODUCTION
689 II. BACKGROUND ON CELL SUBPOPULATIONS 690 III. CHARACTERIZATION OF
TUMOR CELL SUBPOPULATIONS 691 IV. CELL SUBPOPULATIONS INFLUENCING THE
OVERALL TUMOR RESPONSE TO THERAPY 693 V. IMPROVING THE THERAPEUTIC
INTERACTION THROUGH THERAPY COMBINATIONS DIRECTED AGAINST SPECIFIC TUMOR
CELL SUBPOPULATIONS 702 VI. CONCLUSIONS 709 REFERENCES ; 710 CHAPTER 20
SELECTIVE SYNERGISM AGAINST THE TARGET VERSUS HOST BONE MARROW
PROGENITOR CELLS 715 ELLIN BERMAN AND TAI-TSUNG CHANG I. INTRODUCTION
715 II. AZIDOTHYMIDINE AND RECOMBINANT INTERFERON ALPHA: SYNERGISTIC
EFFECTS AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS VERSUS NORMAL HUMAN
BONE MARROW PROGENITOR CELLS 716 III. CANCER CELL PURGING IN AUTOLOGOUS
BONE MARROW TRANSPLANTATION ... 726 IV. SELECTIVE SYNERGISM: THE ROLE
FOR DATA ANALYSIS USING THE MEDIAN-EFFECT EQUATION IN THE DESIGN OF
CLINICAL DRUG TRIALS 733 V. CONCLUSION 734 REFERENCES 734 INDEX 739
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV004708057 |
| classification_rvk | XI 3200 |
| ctrlnum | (OCoLC)231275764 (DE-599)BVBBV004708057 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02516nam a2200613 c 4500</leader><controlfield tag="001">BV004708057</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19920403 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">920210s1991 ad|| |||| 00||| undod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0121740900</subfield><subfield code="9">0-12-174090-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)231275764</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV004708057</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">und</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 3200</subfield><subfield code="0">(DE-625)152994:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Synergism and antagonism in chemotherapy</subfield><subfield code="c">ed. by Ting-chao Chou ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">San Diego u.a.</subfield><subfield code="b">Acad. Press</subfield><subfield code="c">1991</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 752 S.</subfield><subfield code="b">Ill., zahlr. graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antagonist</subfield><subfield code="0">(DE-588)4198647-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Agonist</subfield><subfield code="0">(DE-588)4380725-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologischer Antagonist</subfield><subfield code="0">(DE-588)4198682-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Synergie</subfield><subfield code="0">(DE-588)4200199-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Synergie</subfield><subfield code="0">(DE-588)4200199-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakologischer Antagonist</subfield><subfield code="0">(DE-588)4198682-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Pharmakologischer Antagonist</subfield><subfield code="0">(DE-588)4198682-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Synergie</subfield><subfield code="0">(DE-588)4200199-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="4" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="1"><subfield code="a">Agonist</subfield><subfield code="0">(DE-588)4380725-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="5" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="5" ind2="1"><subfield code="a">Antagonist</subfield><subfield code="0">(DE-588)4198647-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="5" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Dingzhao</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002893247&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-002893247</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| id | DE-604.BV004708057 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T16:16:28Z |
| institution | BVB |
| isbn | 0121740900 |
| language | Undetermined |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-002893247 |
| oclc_num | 231275764 |
| open_access_boolean | |
| owner | DE-12 DE-19 DE-BY-UBM DE-355 DE-BY-UBR |
| owner_facet | DE-12 DE-19 DE-BY-UBM DE-355 DE-BY-UBR |
| physical | XVI, 752 S. Ill., zahlr. graph. Darst. |
| publishDate | 1991 |
| publishDateSearch | 1991 |
| publishDateSort | 1991 |
| publisher | Acad. Press |
| record_format | marc |
| spelling | Synergism and antagonism in chemotherapy ed. by Ting-chao Chou ... San Diego u.a. Acad. Press 1991 XVI, 752 S. Ill., zahlr. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Literaturangaben Antagonist (DE-588)4198647-7 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Arzneimittelwechselwirkung (DE-588)4003147-0 gnd rswk-swf Agonist (DE-588)4380725-2 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Pharmakologischer Antagonist (DE-588)4198682-9 gnd rswk-swf Synergie (DE-588)4200199-7 gnd rswk-swf Arzneimittelwechselwirkung (DE-588)4003147-0 s Synergie (DE-588)4200199-7 s DE-604 Pharmakologischer Antagonist (DE-588)4198682-9 s Chemotherapie (DE-588)4127083-6 s Arzneimittel (DE-588)4003115-9 s Agonist (DE-588)4380725-2 s 1\p DE-604 Antagonist (DE-588)4198647-7 s 2\p DE-604 Zhou, Dingzhao Sonstige oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002893247&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Synergism and antagonism in chemotherapy Antagonist (DE-588)4198647-7 gnd Chemotherapie (DE-588)4127083-6 gnd Arzneimittelwechselwirkung (DE-588)4003147-0 gnd Agonist (DE-588)4380725-2 gnd Arzneimittel (DE-588)4003115-9 gnd Pharmakologischer Antagonist (DE-588)4198682-9 gnd Synergie (DE-588)4200199-7 gnd |
| subject_GND | (DE-588)4198647-7 (DE-588)4127083-6 (DE-588)4003147-0 (DE-588)4380725-2 (DE-588)4003115-9 (DE-588)4198682-9 (DE-588)4200199-7 |
| title | Synergism and antagonism in chemotherapy |
| title_auth | Synergism and antagonism in chemotherapy |
| title_exact_search | Synergism and antagonism in chemotherapy |
| title_full | Synergism and antagonism in chemotherapy ed. by Ting-chao Chou ... |
| title_fullStr | Synergism and antagonism in chemotherapy ed. by Ting-chao Chou ... |
| title_full_unstemmed | Synergism and antagonism in chemotherapy ed. by Ting-chao Chou ... |
| title_short | Synergism and antagonism in chemotherapy |
| title_sort | synergism and antagonism in chemotherapy |
| topic | Antagonist (DE-588)4198647-7 gnd Chemotherapie (DE-588)4127083-6 gnd Arzneimittelwechselwirkung (DE-588)4003147-0 gnd Agonist (DE-588)4380725-2 gnd Arzneimittel (DE-588)4003115-9 gnd Pharmakologischer Antagonist (DE-588)4198682-9 gnd Synergie (DE-588)4200199-7 gnd |
| topic_facet | Antagonist Chemotherapie Arzneimittelwechselwirkung Agonist Arzneimittel Pharmakologischer Antagonist Synergie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002893247&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT zhoudingzhao synergismandantagonisminchemotherapy |